Differential expression of microRNAs associated with estrogen receptor α and progesterone receptor in type Ⅰ and typeⅡendometrial adenocarcinomas
10.3760/cma.j.issn.0529-567x.2009.10.010
- VernacularTitle:与雌、孕激素受体相关的微小RNA在Ⅰ型和Ⅱ型子宫内膜癌中的差异表达
- Author:
Jing ZHOU
;
Keng SHEN
;
Jianfang ZENG
;
Jiaxin YANG
;
Dongyan CAO
;
Quancai GUI
- Publication Type:Journal Article
- Keywords:
Endometrial neoplasm;
MicroRNAs;
Receptors;
estrogen;
Receptors;
progesterone;
Microarray analysis
- From:
Chinese Journal of Obstetrics and Gynecology
2009;44(10):765-770
- CountryChina
- Language:Chinese
-
Abstract:
Objective To identify differentially expression of microRNAs associated with expression of estrogen receptor α(ERα)and progesterone receptor(PR)between type Ⅰ and type Ⅱ endometrial adenocarcinoma.Methods Two kinds of endometrial adenocarcinoma cell lines,Ishikawa and KLE,was transplanted into node mice and biopsied to identify the expression of ERα,PR and p53,and test their response to estrogen and progesterone.Cultured the two cell lines under the estrogen-free and progesteronefree circumstance,total RNA was isolated to identify the differentially expressed microRNAs by microarray for prediction the microRNAs which target ESR1 and PGR by software miRANDA and TargetScan,and then was validated by real-time PCR in two cell lines cultured both in vivo and in vitro and ten specimens from patients.Results Ishikawa cell line was confirmed from type Ⅰ endometrial adenocarcinoma.KLE cell line was confirmed from typeⅡendometrial adenocarcinoma.One hundred and twenty-six differentially expressed microRNAs between the two cell lines were identified by mieroRNA microarray,among of which may target ESR1 inchded hsa-miR-100,99a,and may tgrget PGR included hsa-miR-378,768-3p-The differential expression of hsa-miR-100,99a,378,768-3p identified by microarray between Ishikawa and KLE in vivo and in vitro was equal to that by real-time PCR,while Hsa-miR-100 was significantly down expressed in type Ⅰ group specimens compared to type Ⅱ group(P＜0.01).Conclusion Hsa-miR-100 is significantly down-expressed in type Ⅰ endometrial adenocarcinoma compared to type Ⅱ,which may be a great potential to target ESR1.
